GLPwatch
Soliqua for Chronic kidney disease
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSoliqua (lixisenatide) is not FDA-approved for chronic kidney disease, and any use for this condition is off-label or investigational. The listed research explores lixisenatide’s effects on kidney-related outcomes in diabetes but does not establish its approval for treating chronic kidney disease.
AI summary of the sources below.
| Drug | Soliqua (lixisenatide) |
|---|---|
| Condition | Chronic kidney disease |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Soliqua is not FDA-approved for chronic kidney disease; the research below reflects investigational or off-label study only.
Research on lixisenatide for chronic kidney disease (7)
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
- Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
- Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
- Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.
- Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
- Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
- Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.